Algeta appoints Dr. Donald Coppen as Business Development Director
Algeta ASA announced that it has appointed Donald Coppen as business development Director.
Dr. Coppen will join Chief Business Officer Roger Harrison in driving Algeta's business development strategy aimed at advancing its Thorium payload technology for creating novel targeted cancer therapies, and expanding the Company's pipeline of product candidates.
Dr. Coppen joins Algeta from Biocompatibles International (now part of BTG plc), a UK-based oncology company developing drug-device combination products, where he was Director, Partnering & Licensing. He has previously held project leadership and managerial roles at Lonza Biologics in the UK, and within the crop protection division of Cyanamid International, part of Wyeth (now Pfizer), in Belgium.
Dr. Coppen has a PhD from the University of Southampton and a MBA from the Cranfield School of Management.
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Nanobodies from Camels Enable the Study of Organ Growth
Powering off TB: New electron transport gene is a potential drug target
Aortic aneurysm treatable with asthma drugs
TSRI scientists take step toward mapping how the brain stores memories

New study on the male contraceptive pill - Researchers launch contraceptive startup
Crucell Gains Approval and Moves to Recruitment for West Nile Vaccine Phase I Clinical Study
